REVIEW

The impact of thyroid hormone dysfunction on ischemic heart disease

Madalena von Hafe¹, João Sergio Neves¹,², Catarina Vale¹, Marta Borges-Canha¹,² and Adelino Leite-Moreira¹

¹Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal
²Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar São João, Porto, Portugal

Correspondence should be addressed to J S Neves: joaosergioneves@gmail.com

Abstract

Thyroid hormones have a central role in cardiovascular homeostasis. In myocardium, these hormones stimulate both diastolic myocardial relaxation and systolic myocardial contraction, have a pro-angiogenic effect and an important role in extracellular matrix maintenance. Thyroid hormones modulate cardiac mitochondrial function. Dysfunction of thyroid axis impairs myocardial bioenergetic status. Both overt and subclinical hypothyroidism are associated with a higher incidence of coronary events and an increased risk of heart failure progression. Endothelial function is also impaired in hypothyroid state, with decreased nitric oxide-mediated vascular relaxation. In heart disease, particularly in ischemic heart disease, abnormalities in thyroid hormone levels are common and are an important factor to be considered. In fact, low thyroid hormone levels should be interpreted as a cardiovascular risk factor. Regarding ischemic heart disease, during the late post-myocardial infarction period, thyroid hormones modulate left ventricular structure, function and geometry. Dysfunction of thyroid axis might even be more prevalent in the referred condition since there is an upregulation of type 3 deiodinase in myocardium, producing a state of local cardiac hypothyroidism. In this focused review, we summarize the central pathophysiological and clinical links between altered thyroid function and ischemic heart disease. Finally, we highlight the potential benefits of thyroid hormone supplementation as a therapeutic target in ischemic heart disease.

Introduction

Thyroid hormones (THs) play fundamental roles in cardiovascular homeostasis (1). Given that cardiovascular diseases are among the most prevalent illnesses worldwide, causing substantial mortality, morbidity and hospitalization, an understanding of the role of THs in the cardiovascular system is imperative (1). The main goal of this manuscript is to review the central pathophysiological and clinical links between altered thyroid function and cardiovascular diseases, particularly in ischemic heart disease.

Thyroid hormones

Nearly all organs have thyroid receptors and are in some way regulated by the thyroid axis (2). THs are produced by the thyroid gland, which is mainly regulated by thyroid-stimulating hormone (TSH). TSH is secreted by the pituitary gland and is regulated by thyrotropin-releasing hormone (TRH) secreted by the hypothalamus (2). Ninety percent of the TH secreted is thyroxine (T4) and the remaining 10% is triiodothyronine (T3) (3). T3 is 20 times more potent than T4, making T3 the biologically active hormone of the thyroid axis (3).
Most T3 is generated peripherally from T4 conversion by deiodinases (Fig. 1). These enzymes are also responsible for converting THs into inactive isomers such as reverse T3 (rT3) and 3,3-diiodothyronine (T2). There are three deiodinases with different functions: (1) type 1 deiodinase (D1) is localized in the plasma membrane and is expressed in the liver, thyroid and kidney; this enzyme is mainly responsible for the peripheral conversion of T4 into T3; (2) type 2 deiodinase (D2) seems to be more efficient than D1; the major role of this enzyme is to regulate the intracellular concentration of T3, converting T4 into T3, especially in the brain, pituitary gland and skeletal muscle; and (3) type 3 deiodinase (D3) irreversibly inactivates THs generating T2 or rT3; thus, by lowering the levels of these hormones, D3 is considered an important regulator of the thyroid axis (4). Furthermore, THs are mainly active when not bound to transport proteins. Therefore, variations on binding protein levels can change the peripheral activity of THs (5). In order to perform their roles, THs must bind to thyroid hormone receptors. These receptors are intracellular DNA-binding proteins that bind as hormone-receptor complexes to thyroid hormone response elements (TREs) in the regulatory regions of target genes (6). Consequently, THs modulate essential functions in the growth, development and metabolism of a variety of tissues. There are different subtypes of receptors – TRα1, TRα2, TRβ1 and TRβ2 – which have different functions. TRα1 is the subtype most expressed in the myocardium, regulating important genes related to cell growth, contractile function and electrical activity (6, 7). In fact, inhibition of TRα1 was shown to markedly depress postischemic cardiac function in mice (8). Although TRβ1 is also expressed in the myocardium, it is expressed at a lower level (7). Though TRα2 does not bind T3, it is able to bind TRE, thereby exerting a substantial negative effect on gene expression (7).

The effects of thyroid hormones on the cardiovascular system

THs exert a significant impact on the cardiovascular system via both genomic and non-genomic mechanisms. The major effects of THs on the myocardium are mediated by T3 (Table 1), which stimulates nearly all of the transporters and ion channels involved in calcium myocardial fluxes, upregulating sarcoplasmic reticulum calcium-activated ATPase 2 (SERCA2) and Na⁺/K⁺-ATPase and downregulating phospholamban (9). These changes enhance calcium uptake and release by the sarcoplasmic reticulum, stimulating both diastolic myocardial relaxation and systolic myocardial contraction (9). The contractile apparatus of the cardiac myocyte has two subtypes of myosin heavy chains (MHCs): α-MHC and β-MHC – fast and slow myosin, respectively. T3 can upregulate α-MHC and downregulate β-MHC (10). Therefore, the myocardial hypothyroid state induces a so-called fetal gene reprogramming which increases the expression of β-MHC and decreases the expression of α-MHC and SERCA2 (11). This phenotype presents substantial implications on myocardial function and subsequent progression to heart failure (12). The fetal pattern is characterized by a preference for glucose over fatty acids as a substrate. Although such changes may lower oxygen demands, the yield of ATP per substrate also decreases, resulting in metabolic inefficiencies that decrease metabolic reserves – perhaps leading to cardiac pump dysfunction (12). Nevertheless, this phenotype seems to be reversible with the appropriate therapy (13).
T3 is able to modify the activity of sodium, potassium and calcium channels, altering a variety of intracellular pathways in cardiac and vascular smooth-muscle cells. Consequently, THs can increase resting heart rate, cardiac contractility and venous tone almost immediately, increasing cardiac preload and cardiac output (14). T3 increases myocardial sensitivity to the adrenergic system by increasing the number of adrenergic membrane receptors. Additionally, T3 decreases systemic vascular resistance through vascular smooth-muscle relaxation, which in turn decreases renal perfusion and leads to renin-angiotensin-aldosterone axis activation (15, 16). The relaxation of vascular smooth muscle may lead to an increase in cardiac oxygenation. T3 increases metabolic and oxygen consumption, thereby enhancing the release of vasodilatory mediators (15). THs exhibited a dose-dependent direct effect in rat coronary arteries within a few seconds, indicating a non-genomic mechanism (17). Other effects of T3 that depend at least partially on non-genomic mechanisms include an increase in resting heart rate and left ventricular contractility (17). Non-genomic effects are poorly understood but are an important accessory mechanism in THs actions. These effects are receptor independent and regulate ion transporter activity in the plasma membrane (10). The non-genomic actions of THs in the myocardium involve different signaling cascades, such as cyclic adenosine monophosphate and protein kinases (18). A structural protein of the plasma membrane has been identified as a cell-surface receptor for THs. This receptor is an integrin αvβ3 that interacts with a variety of extracellular matrix proteins and induces serine-threonine kinase pathway (19). THs induce a rapid vascular relaxation that is mediated by NO produced by vascular smooth-muscle and endothelial cells. This is associated with the induction of phosphatidylinositol 3-kinase/protein (PI3K/Akt) signaling pathway. Oxidized low-density lipoprotein (LDL) may blunt the non-genomic action of THs and impair the NO production in endothelial cells (20). Furthermore, THs have a proangiogenic effect, stimulating arteriolar growth in the normal heart as well as after myocardial infarction (21). This proangiogenic effect is mediated by increased transcription of proangiogenic genes and expression of hypoxic inducible factor-1α (HIF-1α) and mediated by activation of integrin αvβ3 (19, 22). T3-induced angiogenesis has been observed in several experimental rat models of ischemia, hypertension and diabetic cardiomyopathy (23).

The therapeutic targets of cardioprotection should not be limited to cardiomyocytes, but should also include other cells such as fibroblasts and endothelial cells that play important roles in preserving myocardial function. THs can modulate metalloproteinases (MMP), increasing MMP 1 and 2 as well as collagen gene expression; consequently, they may have an important impact on the extracellular matrix of the heart (24). Tissue inhibitors of MMP are downregulated by THs (24). The antifibrotic effect of T3 is suggested by evidence that early T3 replacement after ischemia/reperfusion in rats is associated with a reduction in scar size (25). Moreover, hypothyroid status is marked by an increased susceptibility to collagen deposition and cardiac fibrosis (26).

**Table 1** T3-regulated genes.

<table>
<thead>
<tr>
<th>Positively regulated</th>
<th>Negatively regulated</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-MHC</td>
<td>β-MHC</td>
</tr>
<tr>
<td>SERCA2</td>
<td>Phospholamban</td>
</tr>
<tr>
<td>Na+/K' ATPase</td>
<td>p53 and JNK</td>
</tr>
<tr>
<td>β 1-adrenergic receptor</td>
<td>p38/MAPK</td>
</tr>
<tr>
<td>NRF1, NRF2</td>
<td></td>
</tr>
<tr>
<td>HIF-1α, mt-TFA, PPARC1α</td>
<td></td>
</tr>
<tr>
<td>PGC-1α</td>
<td></td>
</tr>
<tr>
<td>Bcl-2 (antiapoptotic)</td>
<td></td>
</tr>
<tr>
<td>HSP27, HSP70</td>
<td></td>
</tr>
</tbody>
</table>

**Thyroid hormone as a cardiac mitochondrial regulator**

THs modulate cardiac mitochondrial function by increasing mitochondrial mass, respiration, oxidative phosphorylation, enzyme activity and mitochondrial protein synthesis such as that of cytochrome as well as phospholipid and mtDNA content (27). Changes in the levels of circulating THs may impair myocardial bioenergetic status with consequences on cardiac function (28, 29). Mitochondrial dysfunction plays a central role in cardiac dysfunction and in the occurrence and progression of heart failure (30). The regulation of mitochondrial function and biogenesis by THs is an emerging mechanism in the therapeutics of cardioprotection. THs promote the upregulation of proteins that are functionally relevant to the rescue of mitochondrial function. Consequently, these hormones may reduce cardiomyocyte loss in the peri-infarct zone. Reversal of the post-ischemic decline of TH levels has been shown to downregulate tumor suppressor protein (p53) possibly via the upregulation of miRNA 30a (31). Additionally, premature activation of the c-Jun N-terminal kinase (JNK) cascade occurs minutes after myocardial infarction. JNK protein expression is associated with apoptosis in the infarction border zone, cardiac dilatation and pathological remodeling (32).
Given that p53 can regulate the JNK pathway through a positive feedback loop, THs might reduce JNK levels through a p53-dependent mechanism (31). T3 treatment (14 ng/g body weight, dose given daily) for 3 days after acute myocardial infarction in rats reduced myocyte apoptosis in the border area, possibly via Akt signaling (33).

T3 administration in rats significantly increases the expression of transcription factors implicated in mitochondrial biogenesis, including nuclear regulatory factors – NRF-1 and NRF-2 which mediate the expression of HIF-1α, mitochondrial transcription factor A (mt-TFA) and peroxisome proliferator-activated receptor coactivator-1α (PPARc-1α), particularly in the peri-infarct zone (34). In fact, the overexpression of mt-TFA and HIF-1α can limit left ventricular remodeling and preserve cardiac performance after myocardial infarction (35, 36, 37). THs also enhance transcriptional coactivators such as peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC-1α) which modulate the regulatory function of many factors (38). Additionally, PGC-1α also induces D2, which generates local THs and further enhances mitochondrial function (38). Downregulation of cytochrome c oxidase I (CcO-I) – a key enzyme of the mitochondrial respiratory chain – occurs in the border zone of infarcted tissue. THs increase mitochondrial proliferation, mitochondrial protein synthesis and cytochrome content. T3 treatment in rats attenuate the downregulation in CcO-I (27, 39). Ischemic/reperfusion injury (IRI) damages the mitochondrial outer membrane, and together with the activation of the proapoptotic proteins, enhances mitochondrial outer membrane permeabilization, releasing cytochrome c, activating caspases and increasing apoptosis (40). THs increase the expression of antiapoptotic protein Bcl-2, reducing the Bax:Bcl-2 ratio and improving cardiac function in infarcted rats (41). Furthermore, THs can prevent oxidative damage in the heart by limiting ROS levels (42). T3 also protects cardiomyocytes against oxidative stress-mediated cell death by opening the protective mitochondrial ATP-dependent K+ channel (mitoKATP) in rescued mitochondria (27). T3 replacement after myocardial infarction might offer a highly successful therapeutic strategy to improve myocardial mitochondrial function and cardiac cell metabolism, limiting infarct-scar size and preventing heart failure (34).

**Cardiovascular effects of hyperthyroidism**

Hyperthyroidism is characterized biochemically by low TSH levels and elevated free T4, free T3 or both. The prevalence of overt hyperthyroidism in the general population is 0.5% (43). Although the effects of THs might be beneficial for cardiovascular function, when exacerbated as they are in hyperthyroidism, they can be detrimental. THs increase resting heart rate, blood volume, myocardial contractility and ejection fraction (Table 2). The most common cardiovascular symptom in patients with hyperthyroidism is palpitation, with 20% exhibiting atrial fibrillation (44). The Rotterdam study, a cross-sectional analysis including 1149 women, showed that elderly women with high/normal thyroid function (low range of normal TSH levels) have an increased risk for atrial fibrillation (45). Systolic function is consistently increased – even at rest – as is the rate of ventricular relaxation and filling (46). At the same time, pulse pressure is wider because of the increased systolic arterial pressure and decreased diastolic arterial pressure due to vasodilatation (Table 2) (47). In patients with hyperthyroidism, cardiac output is notably elevated. Overt hyperthyroidism is associated with increased cardiovascular mortality and 16% increased risk of major cardiovascular events (48). High-output heart failure might be induced by hyperthyroidism even in patients without heart disease (48). Hyperthyroidism is also associated with pulmonary hypertension – albeit less frequently – and atrioventricular valve regurgitation, mainly of the tricuspid valve (49). Heart failure is the main cause of increased cardiovascular mortality in both overt hyperthyroidism and subclinical hyperthyroidism (50).

Subclinical hyperthyroidism is defined by normal free T4 and free T3 levels with a reduced TSH level. The prevalence of exogenous subclinical hyperthyroidism in patients prescribed with levothyroxine is 15–20% (51). Subclinical hyperthyroidism has been associated with increased all-cause mortality, coronary heart disease (CHD) events and mortality and atrial fibrillation (52, 53). CHD mortality and atrial fibrillation are correlated with TSH levels, being higher with TSH under 0.10 mIU/L when compared with levels between 0.10 and 0.44 mIU/L (54). In a meta-analysis of 55 cohort studies with 1,898,314 patients, subclinical and overt hypothyroidism were associated with higher risks of cardiac mortality and all-cause mortality (55).

**Cardiovascular effects of hypothyroidism**

Hypothyroidism is defined by high TSH levels with low THs levels. The prevalence of overt hypothyroidism in nonpregnant adults is 0.2–2.0% (43). Cardiac dysfunction observed in hypothyroidism is not solely explained by
decreased inotropism and increased peripheral vascular resistance (Table 2). The hypothyroid state results in lower heart rate and decreased myocardial contraction and relaxation, with prolonged systolic and early diastolic time intervals, culminating in advanced stages of heart failure (12). Hypothyroidism is also associated with diastolic hypertension and sinus bradycardia due to sinus node dysfunction (56, 57). Diastolic dysfunction is one of the main cardiac anomalies found in patients with hypothyroidism, both at rest and with exertion. Left ventricular asynchrony is also present in hypothyroidism, which affects diastolic and systolic functions, exercise capacity, and quality of life, rendering potential heart failure patients more symptomatic and worsening their prognosis (58). CHD that occasionally coexists with hypothyroidism may be preexistent and aggravated by thyroid dysfunction. Although less common, pericarditis, pericardial effusion and cardiac tamponade are also potential manifestations of hypothyroidism (56, 57).

Subclinical hypothyroidism (SCH) is defined as serum THs within reference range in the presence of elevated serum TSH levels. SCH can be classified as grade 1 (TSH >4.0 or 4.5, but <10 mIU/L) or grade 2 (TSH >10 mIU/L) (10). The prevalence of SCH in the population varies from 4 to 20%, occurring more frequently in adults older than 65 years of age (59). SCH is also associated with a higher risk of heart failure, morbidity and mortality (50, 60). These patients are also at increased risk of atherosclerosis and coronary events (61). This increased risk of coronary events may be caused by increased cholesterol and homocysteine levels and decreased LDL receptors also seen in patients with overt hypothyroidism (50, 61). Patients with SCH have decreased nitric oxide (NO)-mediated vascular relaxation, which contributes to an increase in vascular resistance and consequently to increased left ventricular afterload (Fig. 2) (62). Several studies have shown that patients with hypothyroidism (both overt and subclinical) exhibit impaired endothelial function that improves with TH replacement therapy (61, 63). In the Rotterdam Study mentioned above, patients with SCH had higher prevalence of aortic calcification and myocardial infarction, especially those who were positive for thyroid autoantibodies (64). Patients with SCH also have a decreased left ventricular global longitudinal strain, especially in the lateral wall and interventricular septum (65). Along with these left ventricular disturbances, neovascularization in cardiac tissue after an ischemic event may be inhibited in SCH. Consequently, this may accelerate cardiac pathological remodeling contributing to the development of heart failure (66). In addition to hypercholesterolemia, increased homocysteine, systemic vascular resistance and oxidative stress described above, SCH might also increase peripheral insulin resistance and activate prothrombotic pathways and hypercoagulability (Fig. 2) (67). SCH may constitute a potentially reversible cardiovascular risk factor, a scenario which should be taken into account as it is present in almost 12% of patients with acute myocardial infarction (10, 67). The risk of cardiac events depends on the severity of hormonal dysfunction, tending to be higher when TSH is ≥7.0 mIU/L and even more evident when the value is ≥10 mIU/L (68).

Another subtype of TH dysfunction called nonthyroidal illness syndrome (NTIS) – also known as euthyroid sick syndrome or low-T3 syndrome – is characterized by a rapid decline in plasma-free THs levels (free T3 and free T4), with a marked elevation of rT3 in critically ill patients (69). TSH level is usually within the reference range, except in severe cases of this syndrome. Local and systemic bioavailability of THs is regulated by aberrant expression of deiodinases, SNPs and novel regulators of expression of deiodinases genes (70). Changes in deiodinases activity are more pronounced in conditions characterized by low tissue perfusion (71). The main mechanism seems to involve reduced activity of the deiodinases that convert T4 to T3 and an increase in deiodinase D3 that converts T4 to rT3 (72). D1 is the main pathway for rT3 clearance. The increase in rT3 is partially explained by a decrease in D1 activity (73).

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Effects of thyroid dysfunction in the cardiovascular system.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypothyroidism: overt or subclinical</strong></td>
<td><strong>Hyperthyroidism: overt or subclinical</strong></td>
</tr>
<tr>
<td>↓ heart rate</td>
<td>↑ heart rate</td>
</tr>
<tr>
<td>↓ inotropism</td>
<td>↑ myocardial contractility</td>
</tr>
<tr>
<td>↑ peripheral vascular resistance</td>
<td>↑ cardiac output</td>
</tr>
<tr>
<td>diastolic hypertension</td>
<td>Wider pulse pressure</td>
</tr>
<tr>
<td>sinus bradycardia</td>
<td>Vasodilatation</td>
</tr>
<tr>
<td>sinus bradycardia</td>
<td>↑ blood volume</td>
</tr>
<tr>
<td>↑ risk of atherosclerosis and dyslipidemia</td>
<td>↓ mean arterial pressure</td>
</tr>
<tr>
<td>Pericarditis, pericardial effusion, cardiac tamponade</td>
<td>Atrial fibrillation, Pulmonary hypertension, atrioventricular valve regurgitation</td>
</tr>
</tbody>
</table>
Peeters et al. evidenced that liver D1 activity was downregulated in critically ill patients and D3 activity in liver and skeletal muscle was induced. Skeletal muscle is an abundant tissue in humans, and it is likely that induction of D3 in this tissue also contributes to the pathophysiology of NTIS (71). As in hemangiomas that increase D3 expression and lead to ‘consumptive hypothyroidism’ (74). Recent studies show that expression of D3 is increased in some pathological contexts in a cell-specific manner, which are cancer, cardiac hypertrophy, myocardial infarction, chronic inflammation or critical illness (75). In NTIS, the decrease in T3-dependent gene expression is independent of circulating T3 concentration, demonstrating that after an ischemic event, there is potent and stable induction of D3 activity in cardiomyocytes, resulting in subsequent local cardiac hypothyroidism (10). This might be mediated by tissue catecholamines and inflammatory responses, via inflammatory cytokines such as tumor necrosis factor-α (TNF-α). In fact, D3 overexpression is a common mark of inflammatory response and is one of the leading events in NTIS, often seen in chronic inflammation (70). Experimental evidence showed that infusion of TNF-α, IFN-α, IL-1 and IL-6 in humans results in a decrease in serum T3, T4 and TSH levels and a rise in rT3 (76, 77, 78). In patients with acute myocardial infarction, the rise in IL-6 is closely linked with a decrease in T3 (79). In fact, IL-6 inhibits 5′-deiodinase activity, thereby reducing the conversion of T4 to T3 (80).

Hypoxia also contributes to decreased T3 levels, as it induces hypoxia-induced factor-1 (HIF-1α) that can activate D3 in the myocardium (81). In most conditions, NTIS seems to be an adaptive, compensatory and beneficial response, decreasing energy consumption in response to inflammation during various critical illnesses (82). Although T3 plays an important role in cardiac function, the impact of NTIS in patients with heart disease is unclear. Nevertheless, increased rT3 may be considered a predictor of both short- and long-term mortality in ischemic heart disease (10). NTIS is often associated with depressed myocardial function and is be a strong predictor of mortality in patients with heart disease, both in acute and chronic conditions (69, 83). Low T3 levels are also associated with dilated cardiomyopathy; indeed, 20–30% of patients with dilated cardiomyopathy have NTIS (11).

The impact of thyroid hormone dysfunction on myocardial ischemia

Myocardial ischemia is a major cause of mortality and morbidity worldwide (84). An understanding of the mechanisms of interaction between THs and their receptors is crucial to assess their impact in myocardial ischemia. TRα1 plays a key role during post-ischemic adaptation as it appears to present dual action and may be able to convert pathologic to physiologic growth depending on its ligand availability (85). In fact, TRα1 overexpression in the nucleus of cardiomyocytes in the absence of adequate THs as ligands may induce pathological hypertrophy and fetal phenotype, with predominant β-MHC expression.
In contrast, higher levels of THs stimulate an α-MHC growth pattern, enhancing more physiological growth (86).

The precise prevalence of NTIS among patients with acute coronary syndrome has not been defined, but a prevalence of 5–35% has been reported in the literature (87). Several studies demonstrated a decrease in T3 and an increase in rT3 concentration in patients after an acute coronary event (88). Some factors may predict a more pronounced decline in T3 levels, such as worsening angina pectoris preceding acute myocardial infarction, known chronic heart failure or previous myocardial infarction and diabetes mellitus (89). Low T3 levels also induce oxidative stress and increase apoptotic rate, which may worsen ventricular dysfunction (90). Therefore, THs levels are an important factor modulating left ventricular structure, function and geometry during the late post-myocardial infarction period (91). Patients with ST-elevation myocardial infarction (STEMI) and alterations in thyroid function have almost a 3.5-fold increased risk of major adverse cardiac events, including cardiogenic shock and death, compared with patients with STEMI and no thyroid disorder (92). In fact, alterations in thyroid function seem to occur more frequently in STEMI than in NSTEMI (non-ST-elevation myocardial infarction), possibly because of poorer short-term prognosis and features of the occlusive coronary thrombus typical of STEMI (88, 92, 93).

Recent evidence indicates that circulating T3 levels are an independent determinant of the recovery of left ventricular ejection fraction 6 months after acute myocardial infarction in humans (94). Friberg et al. found a positive correlation between rT3 levels and 1-year mortality in patients with myocardial infarction, independent of other risk factors (95). In line with these results, a recent study with patients attending a cardiac rehabilitation program after an acute coronary syndrome also reported an association between lower T3 levels and all-cause mortality (96). In patients with myocardial infarction, lower T3 levels have been correlated with increased serum levels of cardiac biomarkers such as troponin T and N-terminal pro-brain natriuretic peptide and with lower left ventricular ejection fraction (97). T3 levels may represent a predictor of the potential recovery of ventricular function (94).

One of the priorities in the treatment of myocardial ischemia is the reestablishment of coronary circulation. Early reperfusion has a great impact on short-term mortality after a myocardial ischemic event (98). Coronary revascularization by either coronary bypass surgery (CABG) or percutaneous coronary intervention (PCI) constitutes the primary option in the treatment of coronary artery disease. Despite its indisputable benefits, reperfusion after a myocardial ischemic event may contribute to adverse cardiac remodeling with possible evolution to heart failure. The pathophysiology of IRI is complex; however, recent evidence suggests that mitochondrial dysfunction may be one of the major mechanisms of IRI (99). The incidence of post-ischemic heart failure remains critical, increasing the risk of both cardiac and all-cause deaths (98). After reperfusion, extracellular washout of accumulated H⁺ ions creates a large gradient that increases the influx of sodium via the Na⁺/H⁺ exchanger. This stimulates the reverse action of the Na⁺/Ca²⁺ exchanger pump, increasing oxidative stress (98). THs improve the balance of proapoptotic and pro-survival signaling pathways which may limit IRI (100). T3 enhances the expression of HIF-1α, limiting the mitochondrial opening of permeability transition pores and thereby protecting the cardiomyocyte from reperfusion injury (101). Serum THs levels after CABG are often decreased (102). In fact, NTIS is reported in 50–75% of patients after cardiac surgery and some authors consider this as a poor prognostic factor and a predictor of mortality (28, 102). Pantos et al. were the first to observe that pretreatment with THs confers protection against IRI in isolated rat hearts in a pattern similar to ischemic preconditioning (1). The interest in the role of THs in cardioprotection is increasing. In fact, THs pretreatment may confer protection against subsequent IRI by inducing pharmacological preconditioning in cardiomyocytes, mainly by enhancing heat-shock protein 27 (HSP27) and heat-shock protein 70 (HSP70) and decreasing the activation of proapoptotic p38MAPK (1, 102, 103, 104). Recent studies using TH replacement therapy in animal models with regional or global myocardial ischemia followed by revascularization and/or reperfusion showed improved reversal of myocardial dysfunction compared with the absence of TH replacement therapy (69).

Thyroid hormones and cardiovascular risk factors

Overt and SCH are recognized as cardiovascular risk factors (59). In fact, thyroid disorders are associated with dyslipidemia, insulin resistance, hypertension, inflammation, atherosclerosis and other conditions (48). Hyperlipidemia seen in hypothyroidism is probably due to reduced cholesterol clearance, attributable to reduced hepatic LDL receptors and a decrease in 7α-hydroxylase levels in the liver (10). Elevated serum levels of total

https://doi.org/10.1530/EC-19-0096

© 2019 The authors
Published by Bioscientifica Ltd
cholesterol, LDL cholesterol and apolipoprotein B are nearly reversed following THs therapy in patients with overt hypothyroidism (105). A recent meta-analysis found a statistically significant decrease of 9% in total cholesterol and 14% in LDL cholesterol in patients treated with levothyroxine (doses used vary from 67.5 μg/day to 85.5 μg/day) compared with the placebo group (59). While some studies show a decrease in triglyceride levels, other studies detected lower levels of apolipoprotein B-100 in the treated group (106). The role of THs in preventing cardiac ischemia has not been extensively investigated, mainly due to the possibility that THs may increase heart rate and cardiac work (107). However, the anti-ischemic and cardioprotective effects of THs suggest that supplementation may be more beneficial than harmful. Thus, the correction of overt and subclinical thyroid dysfunction may reduce the risk of future CHD and protect cardiomyocytes from future ischemic stress (107). TH replacement therapy may reverse atherosclerosis, lower peripheral vascular resistance and improve myocardial perfusion in patients with hypothyroidism (61). Treatment with levothyroxine in humans, mean dose 85.5 ± 4.3 μg/day, also has an impact on other predictors of cardiovascular events, such as carotid artery intima-media thickness (106).

Thyroid hormones and the prevention of heart failure after acute coronary events

In order to improve cardiovascular outcomes, cardioprotection represents the new purpose of therapeutic interventions to minimize infarct size and prevent the progression toward heart failure after an acute ischemic event (98). TH replacement therapy shortly after an infarction (or even when delayed) may improve cardiac function, mainly through TRα1 binding (90, 107). THs preserve mitochondrial function and have antifibrotic and proangiogenic effects that are crucial to the prevention of heart failure (98). As described above, after an ischemic event, THs increase MHC-α and the SERCA/PLB ratio which may improve contractile indices and energy expenditure (107, 108). The known effects of THs on MMP include decreased cardiac scar area and improved left ventricular relaxation (23). THs also reduce myocyte apoptosis in the myocardial infarction border area shortly after an ischemic event (23). Rajagopalan et al. observed an improved left ventricular ejection fraction without significant changes in heart rate in adult female rats treated with approximately 6 μg/kg/day of T3 after left coronary artery ligation (109). Moreover, atrial tachyarrhythmia was reduced by 88% in the T3-supplemented group (109). In an animal model of NTIS after an ischemic event, a subcutaneous infusion of 6 μg/kg/day of T3, a physiological or near-physiological dose, improved mitochondrial function, reducing cardiomyocyte loss in the peri-infarct zone (110). Another study in dogs with induced ischemia reported that plasma T3 levels decreased significantly during the ischemic period and continued to fall after reperfusion. The deterioration of left ventricular function was worse in untreated dogs compared with dogs treated with T3, in which hemodynamic function was maintained and improved to levels higher than those in the controls (111).

It is well recognized that chronic treatment with β-blockers improves left ventricular contractility and cardiac remodeling after myocardial infarction (101). A recent study by Zhang et al. aimed to compare T3 and metoprolol treatment in rats with myocardial infarction (101). The treatment with T3 (5 μg/kg/day) or metoprolol (100 mg/kg/day) was given in drinking water immediately after surgery for 8 weeks. Both treatments enhanced left ventricular contractility compared to the placebo and decreased the incidence of atrial tachyarrhythmia (101). Compared to the placebo, histological analysis indicated a significant reduction of 19% in the infarct area in the T3-treated group, which was similar to the group treated with metoprolol (101). Furthermore, the diameter of the left atrium was significantly enlarged after myocardial infarction. While this was ameliorated by T3, the metoprolol group showed results similar to the control group (101). The reversal of fetal genes expression induced by T3 treatment was not as complete upon treatment with metoprolol, suggesting additional improvement in physiological parameters with T3 treatment compared with metoprolol treatment (101).

Thyroid hormones: a future therapeutic option?

Given that the thyroid axis plays a key role in cardiovascular regulation, a thorough understanding its functions may be useful in preventing CHD, reducing ischemic lesions and improving the outcomes of acute coronary events. Although it is known that THs levels in plasma decrease after an ischemic event, the physiological relevance of this remains uncertain and the benefits of THs treatment is controversial. Regarding SCH, current guidelines recommend that it be treated during pregnancy in symptomatic patients according to individual factors.
Myocardial infarction are still unknown and require further investigation. At the time of this review, clinical interventional studies involving THs supplementation are available in patients undergoing CABG surgery or with chronic heart failure (117). The randomized clinical trials known as the THIRST study (98) and ThyAMI (120) are the first clinical trials investigating the use of THs treatment in acute myocardial infarction. The recently published THIRST study is a phase II, randomized, double-blind, placebo-controlled study involving the administration of T3 (maximum dosage 15 μg/m²/die) in patients with acute myocardial infarction treated with primary angioplasty with free T3 levels below the lower reference range (121). This study showed that T3 therapy is safe and improves regional dysfunction in patients with STEMI and NTIS. The results reveal the absence of major or minor side effects induced by T3 treatment such as arrhythmias and increased heart rate (121). In fact, T3-treated patients had a lower incidence of arrhythmias and slower heart rate at follow-up (98). Untreated group had significantly higher TSH compared to T3-treated group at discharge and after 1-month follow-up (121). Cardiac magnetic resonance showed a significant reduction in the global size of necrosis, while regional systolic function tended to improve (121). At follow-up, both groups experienced a significant reduction in wall motion score index, but the difference value (discharge/follow-up) was significantly higher in treated group (121). Additionally, T3-treated group had a significantly increased stroke volume at follow-up and there was a tendency to higher increase in stroke volume compared to the untreated group (121). Given that the study imposed restrictive inclusion criteria that caused difficulties in the enrollment of patients, additional data are necessary to assess clinical targets and treatment doses using this approach (121). The results of ThyAMI and other studies will be essential to gain a better understanding of the effects of THs in ischemic heart disease and to further characterize the therapeutic potential of THs in this context.

The use of oral T3 as a pretreatment (125 μg/day for seven days prior to surgery) in patients undergoing CABG with LV dysfunction improved post-ischemic recovery of cardiac function and significantly lowered the mean inotropic requirements (122). In this study, the treated group exhibited no changes in blood pressure, heart rate, or cardiac rhythm (122). In fact, the low levels of T3 resulting from CABG can be reversed by oral T3 administration to patients with LV dysfunction. Although no differences between groups in the incidence of death and myocardial ischemia were reported, the length of stay...
in ICU was shorter in the treated group (122). Klemperer et al. showed that T3 treatment at reperfusion in patients undergoing CABG increased cardiac output and lowered systemic vascular resistance (14). In isolated dogs’ hearts, T3 treatment after reperfusion increased coronary blood flow by decreasing coronary arterial resistance (123). Additionally, T3 treatment at reperfusion in patients after CABG improved cardiac index decreased cardiac troponin I release (124). Other studies show the effect of THs supplementation on cardiac hemodynamics after acute myocardial infarction. Ojamaa et al. reported increased ejection fraction in rats after administration of 1.2 µg/day of T3 for 1 week after acute myocardial ischemia (125). Administration of 3.0 µg/day of T3 plus 12 µg/day of T4 for 2 weeks after acute myocardial ischemia in rats increases ejection fraction, decreases wall tension and improves left ventricular geometry (126). In isolated rat hearts, T3 was demonstrated to have cardioprotective properties during reperfusion after ischemia as evidenced by reduced LDH release and increased contractile recovery (127). In isolated dogs hearts, a bolus of T3 (0.2 µg/kg) after reperfusion increased coronary blood flow by decreasing coronary arterial resistance (123). The results of a double-blind, randomized placebo-controlled clinical trial suggested that 0.4 mg/kg taken orally once a day for 4 days before surgery may provide protection against myocardial IRI during cardiac surgery in children by increasing HSP70 and MHC-α expression, inducing pharmacological ischemic preconditioning (128). A study in humans that aimed to evaluate the effects of TH replacement therapy on systolic and diastolic function in SCH patients showed a statistically significantly increase in ejection fraction after five months of levothyroxine therapy (129). In this study the starting dose of levothyroxine was 25 µg, and the euthyroid state was achieved with a mean dose of 60.8 ± 19 µg (129). Another study aimed to compare the effects of long-term, low dose T3 (1.2 µg/100g/day) and T4 (4.8 µg/100g/day) hormone treatment to those provided by aerobic exercise training in rats post-myocardial infarction (130). The T3 and T4 hormone treatment enhanced cardiac function, with infarct size reduction and increased ejection fraction, without differences in heart rate, cardiac output and serum THs levels. Low-dose THs might offer a suitable treatment option after myocardial infarction in patients who are intolerant to aerobic exercise training (130). Evidence suggests that the hypothyroid tissue state may be present independent of normal circulating levels of THs. Therefore, it is important to identify a good biomarker of tissue hypothyroid-like state in order to treat patients effectively. The results are promising so far; experimental and clinical studies demonstrate that THs can limit ischemic injury, attenuate cardiac remodeling, and improve hemodynamics. However, the optimal timing for pretreatment and the treatment dose must be carefully evaluated to maximize the benefits.

Conclusions

It is now recognized that even subtle changes in TH levels can lead to adverse effects in the cardiovascular system. Experimental and clinical evidence suggests a close link between low TH levels and poor prognosis in ischemic heart disease. This condition should therefore be regarded as a cardiovascular risk factor. Accordingly, TH replacement therapy may yield improvements in lipid profiles, potentially reversing myocardial dysfunction and preventing the progression to heart failure. TH replacement treatment exhibits anti-ischemic and cardioprotective effects, acting as a promising target for ischemic heart disease. Moreover, subclinical hypothyroidism treatment and nonthyroidal illness syndrome constitute topics garnering increased interest; recent studies suggest that therapy with physiological doses of T3 are safe and provide beneficial effects on ischemic heart disease. Large clinical trials involving TH replacement treatment are necessary to evaluate the potential benefits on morbidity and mortality in patients with ischemic heart disease, as well as any potential long-term consequences.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

This work was supported by the project DOCanet (Grant number NORTE-01-0145-FEDER-000003), supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF).

Acknowledgments

All figures use templates from Servier Medical Art.

References

1. Pantos CI, Malliopoulos VA, Mourouzis IS, Karamanolis EP, Paizis IA, Steinberg N, Varonos DD & Cokkinos DV. Long-term thyroxine administration protects the heart in a pattern similar to ischemic preconditioning. Thyroid 2002 12 325–329. (https://doi.org/10.1089/10507250252949469)
Thyroid hormones and ischemic heart disease


24 Samuels HH, Tsai JS, Casanova J & Stanley F. Thyroid hormone action: in vitro characterization of solubilized nuclear receptors from rat liver and cultured GH1 cells. Journal of Clinical Investigation 1974 53 853–865. (https://doi.org/10.1172/JCI107825)


26 Kinugawa K, Jeong MY, Bristow MR & Long CS. Thyroid Hormone Induces Cardiac Myocyte Hypertrophy in a thyroid hormone receptor α1-Specific Manner that Requires TAK1 and p38 mitogen-activated protein kinase. Molecular Endocrinology 2005 19 1618–1628. (https://doi.org/10.1210/me.2004-0503)


33 Chen YF, Kobayashi S, Chen J, Redetzke RA, Said S, Liang Q & Gerdes AM. Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction.
Thyroid hormones and ischemic heart disease


59 Abreu IM, Lau E, de Sousa Pinho B & Carvalho D. Subclinical hypothyroidism: to treat or not to treat, that is the question! A systematic review with meta-analysis on lipid profile. Endocrine Connections 2017 6 188–199. (https://doi.org/10.1530/EC-17-0028)


61 Grais IM & Sowers JR. Thyroid and the heart. American Journal of Medicine 2014 127 691–698. (https://doi.org/10.1016/j.amjmed.2014.03.009)


Thyroid hormones and ischemic heart disease


80 Boelen A, Maas MA, Lovik CW, Plavtoet MC & Wiersinga WM. Induced illness in interleukin-6 (IL-6) knock- out mice: a causal role of IL-6 in the development of the low 3,3',5'-triiodothyronine euthyroid sick syndrome. Endocrinology 1996 137 5250–5254. (https://doi.org/10.1210/endo.137.12.8940342)


85 Mai W, Janier MF, Allioli N, Quignodon L, Chuzel T, Flamant F & Samarut J. Thyroid hormone receptor alpha is a molecular switch of cardiac function between fetal and postnatal life. PNAS 2004 101 1033–1037. (https://doi.org/10.1073/pnas.0418431101)


Thyroid hormones and ischemic heart disease

M von Hafe et al.


100 Pantos C & Mourouzis I. Translating thyroid hormone effects into clinical practice: the relevance of thyroid hormone receptor alphal in cardiac repair. Heart Failure Reviews 2015 20 273–282. (https://doi.org/10.1007/s10741-014-9465-4)


102 Yang GZ, Xue FS, Liu YY, Li JX, Liu Q & Liao X. Effects of enteral different-dose-levothyroxine-sodium pretreatment on serum thyroid hormone levels and myocardial ischemia-reperfusion injury. Perfusion 2018 33 584–592. (https://doi.org/10.1177/0267659118769226)


107 Pantos C, Mourouzis I & Cokkinos DV. New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider? Heart Failure Reviews 2011 16 79–96. (https://doi.org/10.1007/s10741-010-9185-3)


113 Iervasi G & Nicolini G. Thyroid hormone and cardiovascular system: from basic concepts to clinical application. Internal and Emergency Medicine 2013 8 S71–S74. (https://doi.org/10.1007/s11739-013-0911-4)

114 Moussa SA, O’Connor LJ, Bergh JJ, Davis FB, Scanlan TS & Davis PJ. The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. Journal of Cardiovascular Pharmacology 2005 46 356–360. (https://doi.org/10.1097/JCP.00000175438.94906.a0)


116 Ocasio CA & Scanlan TS. Design and characterization of a thyroid hormone receptor alpha (Trralph)-specific agonist. ACS Chemical Biology 2006 1 585–593. (https://doi.org/10.1021/cb600311v)


120 Jabbar A, Ingale L, Pearse S, Zaman A & Razvi S. Thyroxine in acute myocardial infarction (ThyrAMI) - levothyroxine in subclinical hypothyroidism post-acute myocardial infarction: study protocol


Received in final form 21 March 2019
Accepted 2 April 2019
Accepted Preprint published online 3 April 2019